Research Article
Evaluation of the Risk of Clinical Deterioration among Inpatients with COVID-19
Table 4
Medications taken before admission and chest CT severity at admission compared to the patient’s evolution to the ICU.
| | Hosp_Intern (n = 59) | ICU (n = 15) | value |
| Used medications | Ceftriaxone | 17 (23.0) | 7 (9.5) | 0.223 | Hydroxychloroquine | 34 (45.9) | 6 (8.1) | 0.221 | Azithromycin | 52 (70.3) | 14 (18.9) | 0.563 | Ivermectin | 27 (36.5) | 11 (14.9) | 0.056 | Enoxaparin | 25 (33.8) | 8 (10.8) | 0.446 | Chlorpromazin | 16 (21.6) | 6 (8.1) | 0.355 |
| Chest CT findings | Bilateral ground-glass opacity | 43 (58.9) | 15 (20.5) | 0.030 | Unilateral ground-glass opacity | 8 (11.0) | 0 (0.0) | | Chest CT gravity | Involvement 25–50% | 12 (16.4) | 4 (5.5) | 0.027 | Involvement > 50% | 1 (1.4) | 3 (4.1) | | Pleural effusion | 1 (1.4) | 2 (2.7) | |
| Chest CT nongravity | Clear | 6 (8.2) | 0 (0.0) | | Involvement < 25% | 38 (52.1) | 6 (8.2) | | Nodules | 14 (19.2) | 0 (0.0) | | Length of stay (days) | 6.2 (±SD: 2.7) | 10.7 (±SD: 8.7) | <0.001 |
|
|
n (%); values were calculated by the Mann–Whitney U test, χ2 test, or Fisher’s exact test. |